The global market for Vasculitis Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Vasculitis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vasculitis Drug.

The Vasculitis Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Vasculitis Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Vasculitis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Vasculitis Drug Market Report

Report Metric	Details
Report Name	Vasculitis Drug Market
CAGR	5%
Segment by Type	Blisibimod CCX-168 Gevokizumab Rituximab Biosimilar Others
Segment by Application	Polyarteritis Nodosa Thrombotic Vasculitis Granulomatous Vasculitis Lymphocytic Vasculitis Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Merck, Bayer, Farmalider, Hainan Pharmaceutical Factory, Shanghaihuangxiang Lantian Pharmaceutical, Huzhou Konch Pharmaceutical, CSPC Ouyi Pharmaceutical, Sino-US Zibo Xinhua-Perrigo Pharmaceutical, Hubei Biocause Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Vasculitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Vasculitis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Vasculitis Drug Market report?

Ans: The main players in the Vasculitis Drug Market are Merck, Bayer, Farmalider, Hainan Pharmaceutical Factory, Shanghaihuangxiang Lantian Pharmaceutical, Huzhou Konch Pharmaceutical, CSPC Ouyi Pharmaceutical, Sino-US Zibo Xinhua-Perrigo Pharmaceutical, Hubei Biocause Pharmaceutical

What are the Application segmentation covered in the Vasculitis Drug Market report?

Ans: The Applications covered in the Vasculitis Drug Market report are Polyarteritis Nodosa, Thrombotic Vasculitis, Granulomatous Vasculitis, Lymphocytic Vasculitis, Others

What are the Type segmentation covered in the Vasculitis Drug Market report?

Ans: The Types covered in the Vasculitis Drug Market report are Blisibimod, CCX-168, Gevokizumab, Rituximab Biosimilar, Others

1 Vasculitis Drug Market Overview

1.1 Product Definition

1.2 Vasculitis Drug by Type

1.2.1 Global Vasculitis Drug Market Value Comparison by Type (2024 VS 2031)

1.2.2 Blisibimod

1.2.3 CCX-168

1.2.4 Gevokizumab

1.2.5 Rituximab Biosimilar

1.2.6 Others

1.3 Vasculitis Drug by Application

1.3.1 Global Vasculitis Drug Market Value by Application (2024 VS 2031)

1.3.2 Polyarteritis Nodosa

1.3.3 Thrombotic Vasculitis

1.3.4 Granulomatous Vasculitis

1.3.5 Lymphocytic Vasculitis

1.3.6 Others

1.4 Global Vasculitis Drug Market Size Estimates and Forecasts

1.4.1 Global Vasculitis Drug Revenue 2020-2031

1.4.2 Global Vasculitis Drug Sales 2020-2031

1.4.3 Global Vasculitis Drug Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Vasculitis Drug Market Competition by Manufacturers

2.1 Global Vasculitis Drug Sales Market Share by Manufacturers (2020-2025)

2.2 Global Vasculitis Drug Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Vasculitis Drug Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Vasculitis Drug, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Vasculitis Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Vasculitis Drug, Product Type & Application

2.7 Global Key Manufacturers of Vasculitis Drug, Date of Enter into This Industry

2.8 Global Vasculitis Drug Market Competitive Situation and Trends

2.8.1 Global Vasculitis Drug Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Vasculitis Drug Players Market Share by Revenue

2.8.3 Global Vasculitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Vasculitis Drug Market Scenario by Region

3.1 Global Vasculitis Drug Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Vasculitis Drug Sales by Region: 2020-2031

3.2.1 Global Vasculitis Drug Sales by Region: 2020-2025

3.2.2 Global Vasculitis Drug Sales by Region: 2026-2031

3.3 Global Vasculitis Drug Revenue by Region: 2020-2031

3.3.1 Global Vasculitis Drug Revenue by Region: 2020-2025

3.3.2 Global Vasculitis Drug Revenue by Region: 2026-2031

3.4 North America Vasculitis Drug Market Facts & Figures by Country

3.4.1 North America Vasculitis Drug Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Vasculitis Drug Sales by Country (2020-2031)

3.4.3 North America Vasculitis Drug Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Vasculitis Drug Market Facts & Figures by Country

3.5.1 Europe Vasculitis Drug Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Vasculitis Drug Sales by Country (2020-2031)

3.5.3 Europe Vasculitis Drug Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Vasculitis Drug Market Facts & Figures by Region

3.6.1 Asia Pacific Vasculitis Drug Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Vasculitis Drug Sales by Region (2020-2031)

3.6.3 Asia Pacific Vasculitis Drug Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Vasculitis Drug Market Facts & Figures by Country

3.7.1 Latin America Vasculitis Drug Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Vasculitis Drug Sales by Country (2020-2031)

3.7.3 Latin America Vasculitis Drug Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Vasculitis Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Vasculitis Drug Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Vasculitis Drug Sales by Country (2020-2031)

3.8.3 Middle East and Africa Vasculitis Drug Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Vasculitis Drug Sales by Type (2020-2031)

4.1.1 Global Vasculitis Drug Sales by Type (2020-2025)

4.1.2 Global Vasculitis Drug Sales by Type (2026-2031)

4.1.3 Global Vasculitis Drug Sales Market Share by Type (2020-2031)

4.2 Global Vasculitis Drug Revenue by Type (2020-2031)

4.2.1 Global Vasculitis Drug Revenue by Type (2020-2025)

4.2.2 Global Vasculitis Drug Revenue by Type (2026-2031)

4.2.3 Global Vasculitis Drug Revenue Market Share by Type (2020-2031)

4.3 Global Vasculitis Drug Price by Type (2020-2031)

5 Segment by Application

5.1 Global Vasculitis Drug Sales by Application (2020-2031)

5.1.1 Global Vasculitis Drug Sales by Application (2020-2025)

5.1.2 Global Vasculitis Drug Sales by Application (2026-2031)

5.1.3 Global Vasculitis Drug Sales Market Share by Application (2020-2031)

5.2 Global Vasculitis Drug Revenue by Application (2020-2031)

5.2.1 Global Vasculitis Drug Revenue by Application (2020-2025)

5.2.2 Global Vasculitis Drug Revenue by Application (2026-2031)

5.2.3 Global Vasculitis Drug Revenue Market Share by Application (2020-2031)

5.3 Global Vasculitis Drug Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Merck

6.1.1 Merck Company Information

6.1.2 Merck Description and Business Overview

6.1.3 Merck Vasculitis Drug Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Merck Vasculitis Drug Product Portfolio

6.1.5 Merck Recent Developments/Updates

6.2 Bayer

6.2.1 Bayer Company Information

6.2.2 Bayer Description and Business Overview

6.2.3 Bayer Vasculitis Drug Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Bayer Vasculitis Drug Product Portfolio

6.2.5 Bayer Recent Developments/Updates

6.3 Farmalider

6.3.1 Farmalider Company Information

6.3.2 Farmalider Description and Business Overview

6.3.3 Farmalider Vasculitis Drug Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Farmalider Vasculitis Drug Product Portfolio

6.3.5 Farmalider Recent Developments/Updates

6.4 Hainan Pharmaceutical Factory

6.4.1 Hainan Pharmaceutical Factory Company Information

6.4.2 Hainan Pharmaceutical Factory Description and Business Overview

6.4.3 Hainan Pharmaceutical Factory Vasculitis Drug Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Hainan Pharmaceutical Factory Vasculitis Drug Product Portfolio

6.4.5 Hainan Pharmaceutical Factory Recent Developments/Updates

6.5 Shanghaihuangxiang Lantian Pharmaceutical

6.5.1 Shanghaihuangxiang Lantian Pharmaceutical Company Information

6.5.2 Shanghaihuangxiang Lantian Pharmaceutical Description and Business Overview

6.5.3 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product Portfolio

6.5.5 Shanghaihuangxiang Lantian Pharmaceutical Recent Developments/Updates

6.6 Huzhou Konch Pharmaceutical

6.6.1 Huzhou Konch Pharmaceutical Company Information

6.6.2 Huzhou Konch Pharmaceutical Description and Business Overview

6.6.3 Huzhou Konch Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Huzhou Konch Pharmaceutical Vasculitis Drug Product Portfolio

6.6.5 Huzhou Konch Pharmaceutical Recent Developments/Updates

6.7 CSPC Ouyi Pharmaceutical

6.7.1 CSPC Ouyi Pharmaceutical Company Information

6.7.2 CSPC Ouyi Pharmaceutical Description and Business Overview

6.7.3 CSPC Ouyi Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2020-2025)

6.7.4 CSPC Ouyi Pharmaceutical Vasculitis Drug Product Portfolio

6.7.5 CSPC Ouyi Pharmaceutical Recent Developments/Updates

6.8 Sino-US Zibo Xinhua-Perrigo Pharmaceutical

6.8.1 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Company Information

6.8.2 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Description and Business Overview

6.8.3 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product Portfolio

6.8.5 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Recent Developments/Updates

6.9 Hubei Biocause Pharmaceutical

6.9.1 Hubei Biocause Pharmaceutical Company Information

6.9.2 Hubei Biocause Pharmaceutical Description and Business Overview

6.9.3 Hubei Biocause Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Hubei Biocause Pharmaceutical Vasculitis Drug Product Portfolio

6.9.5 Hubei Biocause Pharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Vasculitis Drug Industry Chain Analysis

7.2 Vasculitis Drug Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Vasculitis Drug Production Mode & Process Analysis

7.4 Vasculitis Drug Sales and Marketing

7.4.1 Vasculitis Drug Sales Channels

7.4.2 Vasculitis Drug Distributors

7.5 Vasculitis Drug Customer Analysis

8 Vasculitis Drug Market Dynamics

8.1 Vasculitis Drug Industry Trends

8.2 Vasculitis Drug Market Drivers

8.3 Vasculitis Drug Market Challenges

8.4 Vasculitis Drug Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Merck

Bayer

Farmalider

Hainan Pharmaceutical Factory

Shanghaihuangxiang Lantian Pharmaceutical

Huzhou Konch Pharmaceutical

CSPC Ouyi Pharmaceutical

Sino-US Zibo Xinhua-Perrigo Pharmaceutical

Hubei Biocause Pharmaceutical

List of Tables

Table 1. Global Vasculitis Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Vasculitis Drug Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Vasculitis Drug Market Competitive Situation by Manufacturers in 2024

Table 4. Global Vasculitis Drug Sales (K Pcs) of Key Manufacturers (2020-2025)

Table 5. Global Vasculitis Drug Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Vasculitis Drug Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Vasculitis Drug Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Vasculitis Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Vasculitis Drug, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Vasculitis Drug, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Vasculitis Drug, Product Type & Application

Table 12. Global Key Manufacturers of Vasculitis Drug, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Vasculitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vasculitis Drug as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Vasculitis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Vasculitis Drug Sales by Region (2020-2025) & (K Pcs)

Table 18. Global Vasculitis Drug Sales Market Share by Region (2020-2025)

Table 19. Global Vasculitis Drug Sales by Region (2026-2031) & (K Pcs)

Table 20. Global Vasculitis Drug Sales Market Share by Region (2026-2031)

Table 21. Global Vasculitis Drug Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Vasculitis Drug Revenue Market Share by Region (2020-2025)

Table 23. Global Vasculitis Drug Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Vasculitis Drug Revenue Market Share by Region (2026-2031)

Table 25. North America Vasculitis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Vasculitis Drug Sales by Country (2020-2025) & (K Pcs)

Table 27. North America Vasculitis Drug Sales by Country (2026-2031) & (K Pcs)

Table 28. North America Vasculitis Drug Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Vasculitis Drug Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Vasculitis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Vasculitis Drug Sales by Country (2020-2025) & (K Pcs)

Table 32. Europe Vasculitis Drug Sales by Country (2026-2031) & (K Pcs)

Table 33. Europe Vasculitis Drug Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Vasculitis Drug Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Vasculitis Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Vasculitis Drug Sales by Region (2020-2025) & (K Pcs)

Table 37. Asia Pacific Vasculitis Drug Sales by Region (2026-2031) & (K Pcs)

Table 38. Asia Pacific Vasculitis Drug Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Vasculitis Drug Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Vasculitis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Vasculitis Drug Sales by Country (2020-2025) & (K Pcs)

Table 42. Latin America Vasculitis Drug Sales by Country (2026-2031) & (K Pcs)

Table 43. Latin America Vasculitis Drug Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Vasculitis Drug Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Vasculitis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Vasculitis Drug Sales by Country (2020-2025) & (K Pcs)

Table 47. Middle East and Africa Vasculitis Drug Sales by Country (2026-2031) & (K Pcs)

Table 48. Middle East and Africa Vasculitis Drug Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Vasculitis Drug Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Vasculitis Drug Sales (K Pcs) by Type (2020-2025)

Table 51. Global Vasculitis Drug Sales (K Pcs) by Type (2026-2031)

Table 52. Global Vasculitis Drug Sales Market Share by Type (2020-2025)

Table 53. Global Vasculitis Drug Sales Market Share by Type (2026-2031)

Table 54. Global Vasculitis Drug Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Vasculitis Drug Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Vasculitis Drug Revenue Market Share by Type (2020-2025)

Table 57. Global Vasculitis Drug Revenue Market Share by Type (2026-2031)

Table 58. Global Vasculitis Drug Price (USD/Pcs) by Type (2020-2025)

Table 59. Global Vasculitis Drug Price (USD/Pcs) by Type (2026-2031)

Table 60. Global Vasculitis Drug Sales (K Pcs) by Application (2020-2025)

Table 61. Global Vasculitis Drug Sales (K Pcs) by Application (2026-2031)

Table 62. Global Vasculitis Drug Sales Market Share by Application (2020-2025)

Table 63. Global Vasculitis Drug Sales Market Share by Application (2026-2031)

Table 64. Global Vasculitis Drug Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Vasculitis Drug Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Vasculitis Drug Revenue Market Share by Application (2020-2025)

Table 67. Global Vasculitis Drug Revenue Market Share by Application (2026-2031)

Table 68. Global Vasculitis Drug Price (USD/Pcs) by Application (2020-2025)

Table 69. Global Vasculitis Drug Price (USD/Pcs) by Application (2026-2031)

Table 70. Merck Company Information

Table 71. Merck Description and Business Overview

Table 72. Merck Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 73. Merck Vasculitis Drug Product

Table 74. Merck Recent Developments/Updates

Table 75. Bayer Company Information

Table 76. Bayer Description and Business Overview

Table 77. Bayer Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 78. Bayer Vasculitis Drug Product

Table 79. Bayer Recent Developments/Updates

Table 80. Farmalider Company Information

Table 81. Farmalider Description and Business Overview

Table 82. Farmalider Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 83. Farmalider Vasculitis Drug Product

Table 84. Farmalider Recent Developments/Updates

Table 85. Hainan Pharmaceutical Factory Company Information

Table 86. Hainan Pharmaceutical Factory Description and Business Overview

Table 87. Hainan Pharmaceutical Factory Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 88. Hainan Pharmaceutical Factory Vasculitis Drug Product

Table 89. Hainan Pharmaceutical Factory Recent Developments/Updates

Table 90. Shanghaihuangxiang Lantian Pharmaceutical Company Information

Table 91. Shanghaihuangxiang Lantian Pharmaceutical Description and Business Overview

Table 92. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 93. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product

Table 94. Shanghaihuangxiang Lantian Pharmaceutical Recent Developments/Updates

Table 95. Huzhou Konch Pharmaceutical Company Information

Table 96. Huzhou Konch Pharmaceutical Description and Business Overview

Table 97. Huzhou Konch Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 98. Huzhou Konch Pharmaceutical Vasculitis Drug Product

Table 99. Huzhou Konch Pharmaceutical Recent Developments/Updates

Table 100. CSPC Ouyi Pharmaceutical Company Information

Table 101. CSPC Ouyi Pharmaceutical Description and Business Overview

Table 102. CSPC Ouyi Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 103. CSPC Ouyi Pharmaceutical Vasculitis Drug Product

Table 104. CSPC Ouyi Pharmaceutical Recent Developments/Updates

Table 105. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Company Information

Table 106. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Description and Business Overview

Table 107. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 108. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product

Table 109. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Recent Developments/Updates

Table 110. Hubei Biocause Pharmaceutical Company Information

Table 111. Hubei Biocause Pharmaceutical Description and Business Overview

Table 112. Hubei Biocause Pharmaceutical Vasculitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 113. Hubei Biocause Pharmaceutical Vasculitis Drug Product

Table 114. Hubei Biocause Pharmaceutical Recent Developments/Updates

Table 115. Key Raw Materials Lists

Table 116. Raw Materials Key Suppliers Lists

Table 117. Vasculitis Drug Distributors List

Table 118. Vasculitis Drug Customers List

Table 119. Vasculitis Drug Market Trends

Table 120. Vasculitis Drug Market Drivers

Table 121. Vasculitis Drug Market Challenges

Table 122. Vasculitis Drug Market Restraints

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Product Picture of Vasculitis Drug

Figure 2. Global Vasculitis Drug Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Vasculitis Drug Market Share by Type: 2024 & 2031

Figure 4. Blisibimod Product Picture

Figure 5. CCX-168 Product Picture

Figure 6. Gevokizumab Product Picture

Figure 7. Rituximab Biosimilar Product Picture

Figure 8. Others Product Picture

Figure 9. Global Vasculitis Drug Market Value by Application (2020-2031) & (US$ Million)

Figure 10. Global Vasculitis Drug Market Share by Application: 2024 & 2031

Figure 11. Polyarteritis Nodosa

Figure 12. Thrombotic Vasculitis

Figure 13. Granulomatous Vasculitis

Figure 14. Lymphocytic Vasculitis

Figure 15. Others

Figure 16. Global Vasculitis Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Vasculitis Drug Market Size (2020-2031) & (US$ Million)

Figure 18. Global Vasculitis Drug Sales (2020-2031) & (K Pcs)

Figure 19. Global Vasculitis Drug Average Price (USD/Pcs) & (2020-2031)

Figure 20. Vasculitis Drug Report Years Considered

Figure 21. Vasculitis Drug Sales Share by Manufacturers in 2024

Figure 22. Global Vasculitis Drug Revenue Share by Manufacturers in 2024

Figure 23. Global 5 and 10 Largest Vasculitis Drug Players: Market Share by Revenue in Vasculitis Drug in 2024

Figure 24. Vasculitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 25. Global Vasculitis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 26. North America Vasculitis Drug Sales Market Share by Country (2020-2031)

Figure 27. North America Vasculitis Drug Revenue Market Share by Country (2020-2031)

Figure 28. U.S. Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Canada Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Europe Vasculitis Drug Sales Market Share by Country (2020-2031)

Figure 31. Europe Vasculitis Drug Revenue Market Share by Country (2020-2031)

Figure 32. Germany Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. France Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. U.K. Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Italy Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Russia Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Asia Pacific Vasculitis Drug Sales Market Share by Region (2020-2031)

Figure 38. Asia Pacific Vasculitis Drug Revenue Market Share by Region (2020-2031)

Figure 39. China Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Japan Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. South Korea Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. India Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Australia Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Taiwan Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Indonesia Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Thailand Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Malaysia Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Philippines Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Latin America Vasculitis Drug Sales Market Share by Country (2020-2031)

Figure 50. Latin America Vasculitis Drug Revenue Market Share by Country (2020-2031)

Figure 51. Mexico Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Brazil Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Argentina Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Middle East and Africa Vasculitis Drug Sales Market Share by Country (2020-2031)

Figure 55. Middle East and Africa Vasculitis Drug Revenue Market Share by Country (2020-2031)

Figure 56. Turkey Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Saudi Arabia Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. UAE Vasculitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 59. Global Sales Market Share of Vasculitis Drug by Type (2020-2031)

Figure 60. Global Revenue Market Share of Vasculitis Drug by Type (2020-2031)

Figure 61. Global Vasculitis Drug Price (USD/Pcs) by Type (2020-2031)

Figure 62. Global Sales Market Share of Vasculitis Drug by Application (2020-2031)

Figure 63. Global Revenue Market Share of Vasculitis Drug by Application (2020-2031)

Figure 64. Global Vasculitis Drug Price (USD/Pcs) by Application (2020-2031)

Figure 65. Vasculitis Drug Value Chain

Figure 66. Channels of Distribution (Direct Vs Distribution)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions